https://orcid.org/0000-0002-7905-4284
References
- Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–3. doi:https://doi.org/10.1038/nm1267.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–73. doi:https://doi.org/10.1038/s41586-020-2012-7.
- Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003;108:1707–12. doi:https://doi.org/10.1161/01.CIR.0000094734.67990.99.
- Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016;46:239–48. doi:https://doi.org/10.1097/SHK.0000000000000633.
- Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A. 2005;102:7988–93. doi:https://doi.org/10.1073/pnas.0409465102.
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–22. doi:https://doi.org/10.1016/S2213-2600(20)30076-X.
- Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–78. doi:https://doi.org/10.1016/S0140-6736(03)13413-7.
- Nicholls J, Peiris M. Good ACE, bad ACE do battle in lung injury, SARS. Nat Med. 2005;11:821–22. doi:https://doi.org/10.1038/nm0805-821.
- Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–16. doi:https://doi.org/10.1038/nature03712.
- Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med. 2010;38:596–601. doi:https://doi.org/10.1097/CCM.0b013e3181c03009.
- Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52(9):783–92. doi:https://doi.org/10.1007/s40262-013-0072-7.
- Jafari R, Zolbanin NM, Rafatpanah H, Majidi J, Kazemi T. Fc-fusion proteins in therapy: an updated view. Curr Med Chem. 2017;24:1228–37. doi:https://doi.org/10.2174/0929867324666170113112759.
- Liu S, Sun L, Wang C, Cui Y, Ling Y, Li T, Lin F, Fu W, Ding M, Zhang S, et al. Treatment of murine lupus with TIGIT-Ig. Clin Immunol. 2019;203:72–80. doi:https://doi.org/10.1016/j.clim.2019.04.007.
- Fu W, Ma Z, Lei C, Ding M, Hu S. TIGIT-Fc promote immune tolerance at the feto-maternal interface. bioRxiv. 2019;819243.
- Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, Hu S. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11:2070. doi:https://doi.org/10.1038/s41467-020-16048-4.
- Sorrento therapeutics press release. March 20, 2020. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential. Web 25 May 2020.
- Sorrento Therapeutics press release. March 24, 2020. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-collaborates-mabpharm-development-and-commercialization.Web 25 May 2020